Meeting
2014 Gastrointestinal Cancers Symposium
Planned interim analysis of phase II study of sorafenib and capecitabine (SorCape) in previously treated metastatic colorectal cancer (mCRC): NCT01471353.
Authors
Thomas J. George
University of Florida, Gainesville, FL
Thomas J. George , Alison Marguerite Ivey , Karen Colleen Daily , Long H. Dang , Scott Watson , Renee Granicz , Margaret A. McEwan , Joanna Scian , Xiaomin Lu , Atif Iqbal , Sanda Tan , Ivan Zendejas , Carmen Joseph Allegra
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Cancers of the Colon and Rectum
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT01471353
Citation
J Clin Oncol 32, 2014 (suppl 3; abstr 548)
DOI
10.1200/jco.2014.32.3_suppl.548
Abstract #
548
Poster Bd #
C53
Abstract Disclosures
Similar Posters
Poster
2013 Gastrointestinal Cancers Symposium
Phase II study of sorafenib and capecitabine (SorCape) in previously treated metastatic colorectal cancer (mCRC): NCT01471353.
First Author: Thomas George
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Real-world treatment patterns and unmet need in patients with previously treated metastatic colorectal cancer that is not MSI-H or dMMR.
First Author: Kaushal Desai
Poster
2022 ASCO Gastrointestinal Cancers Symposium
BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cet) ± chemotherapy for first-line treatment (tx) of BRAF V600E-mutant (BRAFV600) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A randomized phase II trial of MEK and CDK4/6 inhibitors vesus tipiracil/trifluridine (TAS-102) in metastatic KRAS/NRAS mutant (mut) colorectal cancer (CRC).
First Author: Michael Sangmin Lee